• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Mechanism of thrombolytic enzymes].

作者信息

Matsuo O

机构信息

Department of Physiology, Kinki University School of Medicine.

出版信息

Rinsho Ketsueki. 1993 Apr;34(4):395-402.

PMID:8510325
Abstract

Thrombolytic enzymes belong to plasminogen activator (PA) in blood fibrinolysis and love been used for the efficient thrombolysis is achieved by the administration of PA which has high affinity for fibrin and induces plasminogen activation on the fibrin surface. PA with lower affinity for fibrin can activate plasminogen in circulating plasma, which causes bleeding tendency. At present, 11 PAs which are available for clinical usage or under investigation, are classified into two types: direct-type PA and indirect-type PA. The former which cleaved plasminogen directly and produces plasmin, includes urokinase-type PA, tissue-type PA, single-chain u-PA, bat PA, mutant PA, hybrid PA, IgG carrying PA and bispecific monoclonal antibody. The latter has no biological function by itself and expresses PA activity after forming a complex with plasminogen. This group includes streptokinase, anisoylated plasminogen streptokinase activator complex and staphylokinase. The PA activity of staphylokinase/plasminogen complex is inhibited by alpha 2-plasmin inhibitor, but can be expressed on the fibrin surface. Thus, PA activity of this complex is hardly observed in plasma. These feature of staphylokinase resembles to tissue-type PA.

摘要

相似文献

1
[Mechanism of thrombolytic enzymes].
Rinsho Ketsueki. 1993 Apr;34(4):395-402.
2
Fibrinolysis--a review.纤维蛋白溶解——综述
Ann Clin Lab Sci. 1984 Nov-Dec;14(6):443-9.
3
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.一种针对人纤维蛋白和尿激酶型纤溶酶原激活剂的双特异性单克隆抗体在体外和体内增强血凝块溶解作用。
Thromb Haemost. 1991 Dec 2;66(6):684-93.
4
Fibrinolytic agents: mechanisms of activity and pharmacology.纤维蛋白溶解剂:作用机制与药理学
Thromb Haemost. 1995 Jul;74(1):387-90.
5
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.纤维蛋白溶解的分子机制及其在纤维蛋白特异性溶栓治疗中的应用。
J Cell Biochem. 1987 Feb;33(2):77-86. doi: 10.1002/jcb.240330202.
6
Fibrin-specific thrombolytic agents.纤维蛋白特异性溶栓剂。
Schweiz Med Wochenschr. 1987 Nov 14;117(46):1791-8.
7
Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.纤溶酶原激活剂的纤维蛋白特异性影响纤维蛋白溶解效率及对超声的反应性:九种纤溶酶原激活剂的体外比较
Thromb Haemost. 1999 Apr;81(4):605-12.
8
Fibrin-specific thrombolytic agents.纤维蛋白特异性溶栓剂。
Klin Wochenschr. 1988;66 Suppl 12:15-23.
9
Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.通过在纤溶酶切割位点融合获得的嵌合型(组织型/尿激酶型)纤溶酶原激活剂的特性。
Thromb Haemost. 1993 May 3;69(5):466-72.
10
[New thrombolytic agents].[新型溶栓剂]
Ann Biol Clin (Paris). 1987;45(2):212-8.